CARGO Therapeutics, Inc. (CRGX)

19,51 +0,42 (+2,20%) Börsenschluss: 04:00PM EDT

CARGO Therapeutics, Inc.

1900 Alameda De Las Pulgas
Suite 350
San Mateo, CA 94403
United States
650-379-6143
https://cargo-tx.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 116

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Ms. Gina Chapman	President, CEO & Director	1,09M	N/A	1967
Dr. Crystal L. Mackall M.D.	Co-Founder	160k	N/A	1961
Mr. Anup Radhakrishnan	CFO, Secretary & Chief Business Officer	667,1k	N/A	1980
Dr. Ginna G. Laport M.D.	Chief Medical Officer	538,13k	N/A	1965
Dr. Robbie Majzner M.D.	Founder & Chair of Scientific Advisory Board	N/A	N/A	N/A
Ms. Nancy Goodman J.D.	Founder	N/A	N/A	N/A
Dr. Louai Labanieh	Founder	N/A	N/A	N/A
Mr. Faisal Shawwa M.B.A.	Senior Vice President of Finance & Accounting	N/A	N/A	N/A
Dr. Shishir Gadam Ph.D.	Chief Technical Officer	674,03k	N/A	1967
Dr. Michael Ports Ph.D.	Chief Scientific Officer	N/A	N/A	1981

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

CARGO Therapeutics, Inc., a clinical-stage biotechnology company, develops chimeric antigen receptor (CAR) T-cell therapies for cancer patients. The company's lead program is CRG-022, an autologous CD22 CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in B-cell malignancies. It also develops CRG-023, a tri-specific CAR T product candidate that targets tumor cells with three B-cell antigen targets. The company was formerly known as Syncopation Life Sciences, Inc. and changed its name to CARGO Therapeutics, Inc. in September 2022. CARGO Therapeutics, Inc. was incorporated in 2019 and is headquartered in San Mateo, California.

Corporate Governance

CARGO Therapeutics, Inc.s ISS Governance QualityScore, Stand N/A, lautet N/A. Die grundlegenden Scores sind Audit: N/A, Vorstand: N/A, Shareholderrechte: N/A, Kompensation: N/A.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.